Novel compounds for hypoxic cell therapy and imaging
申请人:Wiebe Leonard
公开号:US20060270610A1
公开(公告)日:2006-11-30
The present invention provides for compounds suitable for therapeutic treatment of hypoxic tissues, particularly for application in radiotherapy, chemosensitization, radiosensitization. The present invention further provides for compounds suitable for radioimaging of hypoxic cells.
The present work describes the synthesis of the β-isomer of 1-α-D-(5-deoxy-5-iodoarabinofuranosyl)-2-nitroimidazole (IAZA). Radioiodinated IAZA (123I-IAZA) has been extensively studied as a radiopharmaceutical for the diagnosis of regional and/or focal tissue hypoxia in a variety of clinical pathologies. The β-anomer of IAZA, 1-β-D-(5-deoxy-5-iodoarabinofuranosyl)-2-nitroimidazole (β-IAZA, 1), was synthesized via an unconventional route starting from 1-β-D-(ribofuranosyl)-2-nitroimidazole (AZR), with a change of configuration at the C-2′-position to afford 1-β-D-(arabinofuranosyl)-2-nitroimidazole (β-AZA, 7). Nucleophilic iodination of the 5′-O-toluenesulfonyl-2′,3′-di-O-acetyl precursor of β-AZA, 9, followed by deprotection, afforded 1 in satisfactory yield. β-IAZA (1) was also synthesized from 7 using molecular iodine and triphenylphosphine.